Aegerion Pharmaceuticals Company Profile (NASDAQ:AEGR)

About Aegerion Pharmaceuticals

Aegerion Pharmaceuticals logoAegerion Pharmaceuticals, Inc. is a biopharmaceutical company engaged in the development and commercialization of therapies for patients with debilitating rare diseases. It operates through pharmaceuticals segment. Its products include lomitapide and metreleptin. Lomitapide is a small molecule microsomal triglyceride transfer protein (MTP) inhibitor. Lomitapide received marketing approval under the brand name Juxtapid (lomitapide) capsules from the United States Food and Drug Administration (FDA) as an adjunct to a low-fat diet and other lipid-lowering treatments. It also received marketing authorization for lomitapide in the European Union (EU) under the brand name LOJUXTA (lomitapide) hard capsules (LOJUXTA) as a treatment for HoFH in adults. Metreleptin is a recombinant human leptin analog that exerts its function by binding to and activating the human leptin receptor. Metreleptin is marketed in the United States under the brand name MYALEPT (metreleptin) for injection (MYALEPT).

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Biotechnology
  • Sub-Industry: Biotechnology
  • Exchange: NASDAQ
  • Symbol: AEGR
  • CUSIP: 00767E10
Key Metrics:
  • Previous Close: $2.49
  • 50 Day Moving Average: $1.86
  • 200 Day Moving Average: $2.19
  • 52-Week Range: $1.23 - $16.63
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: -7.65
  • P/E Growth: -0.05
  • Market Cap: $90.31M
  • Outstanding Shares: 29,514,000
  • Beta: 0.55
Profitability:
  • Net Margins: -80.76%
  • Return on Equity: -128.77%
  • Return on Assets: -25.17%
Debt:
  • Debt-to-Equity Ratio: 21.64%
  • Current Ratio: 1.13%
  • Quick Ratio: 0.77%
Additional Links:
Companies Related to Aegerion Pharmaceuticals:

Analyst Ratings

Consensus Ratings for Aegerion Pharmaceuticals (NASDAQ:AEGR) (?)
Ratings Breakdown: 1 Sell Rating, 2 Hold Ratings, 3 Buy Ratings
Consensus Rating:Hold (Score: 2.33)
Consensus Price Target: $14.83 (384.75% upside)

Analysts' Ratings History for Aegerion Pharmaceuticals (NASDAQ:AEGR)
Show:
DateFirmActionRatingPrice TargetDetails
5/17/2016Leerink SwannBoost Price TargetOutperform$6.00 -> $15.00View Rating Details
4/17/2016Cowen and CompanyReiterated RatingHoldView Rating Details
2/12/2016Bank of America Corp.DowngradeNeutral -> Underperform$6.00View Rating Details
12/21/2015GuggenheimUpgradeSell -> Buy$7.00 -> $13.00View Rating Details
11/11/2015JPMorgan Chase & Co.Reiterated RatingNeutral$24.00View Rating Details
11/10/2015Jefferies GroupLower Price TargetBuy$26.00 -> $16.00View Rating Details
5/26/2015Needham & Company LLCReiterated RatingHoldView Rating Details
10/31/2014Deutsche Bank AGDowngradeBuy -> Hold$58.00 -> $26.00View Rating Details
(Data available from 9/30/2014 forward)

Earnings

Earnings History for Aegerion Pharmaceuticals (NASDAQ:AEGR)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
11/7/2016        
8/9/2016Q2($0.38)($0.72)$35.50 million$44.50 millionViewN/AView Earnings Details
5/16/2016Q1($0.58)($1.72)$43.00 million$35.70 millionViewListenView Earnings Details
2/25/2016Q4($0.89)($0.69)$47.74 million$49.00 millionViewListenView Earnings Details
11/9/2015Q315($0.42)($0.34)$59.72 million$67.30 millionViewN/AView Earnings Details
8/5/2015Q2($0.28)$0.23$58.98 million$64.20 millionViewN/AView Earnings Details
5/4/2015Q414($0.26)$0.06$59.30 millionViewN/AView Earnings Details
2/26/2015Q4$0.08$0.11$49.18 million$51.71 millionViewN/AView Earnings Details
10/30/2014Q314($0.14)($0.20)$48.60 million$43.70 millionViewN/AView Earnings Details
7/29/2014Q214($0.41)($0.33)$35.40 million$36.00 millionViewListenView Earnings Details
5/6/2014Q1($0.35)($0.25)$33.58 million$27.00 millionViewListenView Earnings Details
2/26/2014Q413($0.30)($0.14)$24.51 million$24.50 millionViewListenView Earnings Details
10/29/2013Q313($0.50)($0.43)$13.07 million$16.30 millionViewN/AView Earnings Details
7/30/2013Q2 2013($0.62)($0.66)$4.27 million$6.50 millionViewN/AView Earnings Details
11/7/2012Q312($0.56)($0.59)ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for Aegerion Pharmaceuticals (NASDAQ:AEGR)
Current Year EPS Consensus Estimate: $-3.25 EPS
Next Year EPS Consensus Estimate: $-0.4 EPS
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20162($0.77)$0.09($0.34)
Q2 20163($0.73)($0.01)($0.44)
Q3 20163($0.73)$0.15($0.37)
Q4 20163($0.78)($0.04)($0.42)
(Data provided by Zacks Investment Research)

Dividends

Dividend History for Aegerion Pharmaceuticals (NASDAQ:AEGR)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading History for Aegerion Pharmaceuticals (NASDAQ:AEGR)
Insider Ownership Percentage: 4.60%
Institutional Ownership Percentage: 87.60%
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
9/13/2016Healthcare Master Fun BroadfinMajor ShareholderBuy75,000$1.75$131,250.00View SEC Filing  
9/12/2016Healthcare Master Fun BroadfinMajor ShareholderBuy276,000$1.66$458,160.00View SEC Filing  
8/19/2014Mark J FitzpatrickCFOBuy1,150$30.64$35,236.00View SEC Filing  
7/31/2014Marc D BeerCEOBuy10,000$33.65$336,500.00View SEC Filing  
6/3/2014Marc D BeerCEOBuy10,000$30.12$301,200.00View SEC Filing  
5/27/2014Marc D BeerCEOBuy10,000$31.59$315,900.00View SEC Filing  
5/20/2014Marc BeerCEOBuy10,000$30.53$305,300.00View SEC Filing  
5/8/2014Anne VanlentDirectorBuy4,000$33.78$135,120.00View SEC Filing  
5/8/2014Marc BeerCEOBuy30,000$35.31$1,059,300.00View SEC Filing  
4/30/2014Craig FraserInsiderSell2,250$43.55$97,987.50View SEC Filing  
3/31/2014Craig FraserInsiderSell2,250$46.20$103,950.00View SEC Filing  
3/14/2014Mark SumerayInsiderSell2,000$51.34$102,680.00View SEC Filing  
2/11/2014Craig FraserInsiderSell2,250$67.00$150,750.00View SEC Filing  
12/16/2013Mark SumerayInsiderSell2,000$66.34$132,680.00View SEC Filing  
10/30/2013Marc D BeerCEOSell40,000$87.79$3,511,600.00View SEC Filing  
10/29/2013Sandford D SmithDirectorSell2,502$95.00$237,690.00View SEC Filing  
10/15/2013Mark SumerayInsiderSell2,000$80.33$160,660.00View SEC Filing  
10/7/2013Mark SumerayInsiderSell3,500$93.17$326,095.00View SEC Filing  
9/16/2013Mark SumerayInsiderSell2,000$89.77$179,540.00View SEC Filing  
9/5/2013Perceptive Advisors LlcMajor ShareholderSell750,000$89.20$66,900,000.00View SEC Filing  
8/21/2013David ScheerDirectorSell20,000$84.58$1,691,600.00View SEC Filing  
8/16/2013Mark SumerayInsiderSell2,000$88.71$177,420.00View SEC Filing  
8/15/2013Marc BeerCEOSell60,000$88.54$5,312,400.00View SEC Filing  
8/14/2013Mark FitzpatrickCFOSell7,500$93.44$700,800.00View SEC Filing  
8/12/2013Sandford SmithDirectorSell10,000$92.32$923,200.00View SEC Filing  
7/15/2013Mark SumerayInsiderSell2,000$78.77$157,540.00View SEC Filing  
6/17/2013Mark SumerayInsiderSell6,000$65.27$391,620.00View SEC Filing  
5/15/2013Mark SumerayInsiderSell6,000$47.32$283,920.00View SEC Filing  
2/1/2013Perceptive Advisors LlcMajor ShareholderBuy50,000$27.79$1,389,500.00View SEC Filing  
1/18/2013Perceptive Advisors LlcMajor ShareholderBuy50,000$27.62$1,381,000.00View SEC Filing  
1/17/2013Perceptive Advisors LlcMajor ShareholderBuy50,000$26.73$1,336,500.00View SEC Filing  
1/11/2013Perceptive Advisors LlcMajor ShareholderBuy475,000$27.07$12,858,250.00View SEC Filing  
12/4/2012Perceptive Advisors LlcMajor ShareholderBuy20,000$21.27$425,400.00View SEC Filing  
11/29/2012Perceptive Advisors LlcMajor ShareholderBuy30,000$22.71$681,300.00View SEC Filing  
11/28/2012Perceptive Advisors LlcMajor ShareholderBuy150,000$21.25$3,187,500.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Latest Headlines for Aegerion Pharmaceuticals (NASDAQ:AEGR)
DateHeadline
thestreet.com logoVHT, ABUS, BDSI, AEGR: ETF Outflow Alert (NASDAQ:AEGR)
www.thestreet.com - September 29 at 3:18 PM
streetinsider.com logoAegerion Pharma (AEGR) Announces Approval of Juxtapid in Japan as HoFH Treatment (NASDAQ:AEGR)
www.streetinsider.com - September 29 at 3:18 PM
einnews.com logoAegerion Pharmaceuticals’ JUXTAPID® (lomitapide) Capsules Approved in Japan for the Treatment of Homozygous Familial Hypercholesterolemia (HoFH) (NASDAQ:AEGR)
www.einnews.com - September 29 at 3:18 PM
rttnews.com logoAegerion Pharmaceuticals Inc. (AEGR) Is Up After Japanese Approval For JUXTAPID (NASDAQ:AEGR)
www.rttnews.com - September 29 at 3:18 PM
rttnews.com logoAegerion Pharmaceuticals Inc. (AEGR) Is Up After Japanese ... - RTT News (NASDAQ:AEGR)
www.rttnews.com - September 29 at 8:05 AM
News IconBiotech Stocks To Put On Your Watch List: Cerus Corporation (NASDAQ:CERS), Aegerion Pharmaceuticals, Inc ... - The Voice Registrar (NASDAQ:AEGR)
voiceregistrar.com - September 28 at 8:06 AM
News IconPenny Stock Investors are Growing Curious About Aegerion Pharmaceuticals, Inc. (NASDAQ:AEGR) - Duncan Research (NASDAQ:AEGR)
www.duncanindependent.com - September 27 at 3:20 PM
capitalcube.com logoETF’s with exposure to Aegerion Pharmaceuticals, Inc. : September 27, 2016 (NASDAQ:AEGR)
www.capitalcube.com - September 27 at 3:20 PM
News IconUnder the Microscope: Zeroing in on Shares of Aegerion Pharmaceuticals, Inc. (NASDAQ:AEGR) - Duncan Research (NASDAQ:AEGR)
www.duncanindependent.com - September 26 at 3:20 PM
News IconBiotech Stocks Worth Chasing: Aegerion Pharmaceuticals, Inc ... - The Independent Republic (NASDAQ:AEGR)
theindependentrepublic.com - September 24 at 8:39 AM
globenewswire.com logoAegerion Pharmaceuticals Observes Familial Hypercholesterolemia Awareness Day - GlobeNewswire (press release) (NASDAQ:AEGR)
globenewswire.com - September 24 at 8:39 AM
publicnow.com logoAegerion Pharmaceuticals Observes Familial Hypercholesterolemia Awareness Day (NASDAQ:AEGR)
www.publicnow.com - September 24 at 8:39 AM
News IconKeen Investors Find News on Aegerion Pharmaceuticals, Inc. (NASDAQ:AEGR) - Duncan Research (NASDAQ:AEGR)
www.duncanindependent.com - September 23 at 3:47 PM
News IconUnder the Microscope, Zeroing in at Aegerion Pharmaceuticals, Inc. (NASDAQ:AEGR) - Duncan Research (NASDAQ:AEGR)
www.duncanindependent.com - September 22 at 3:17 PM
News IconHot Biotech Stocks Recap: Aegerion Pharmaceuticals, Inc. (NASDAQ:AEGR), Northwest Biotherapeutics, Inc ... - The Voice Registrar (NASDAQ:AEGR)
voiceregistrar.com - September 22 at 3:17 PM
News IconPenny Stock Investors Take an Interest in Aegerion Pharmaceuticals, Inc. (NASDAQ:AEGR) - Duncan Research (NASDAQ:AEGR)
www.duncanindependent.com - September 21 at 3:52 PM
News IconUnusual Healthcare Active Runners- Palatin Technologies (NYSE:PTN), Aegerion Pharmaceuticals (NASDAQ:AEGR) - Seneca Globe (NASDAQ:AEGR)
www.senecaglobe.com - September 21 at 3:52 PM
News IconBiotech Gainers In Focus- Puma Biotechnology (NYSE:PBYI), Aegerion Pharmaceuticals (NASDAQ:AEGR) - Seneca Globe (NASDAQ:AEGR)
www.senecaglobe.com - September 21 at 3:52 PM
globenewswire.com logoAegerion Pharmaceuticals Appoints Remi Menes as Chief Commercial Officer - GlobeNewswire (press release) (NASDAQ:AEGR)
globenewswire.com - September 21 at 3:52 PM
publicnow.com logoAegerion Pharmaceuticals Appoints Remi Menes as Chief Commercial Officer (NASDAQ:AEGR)
www.publicnow.com - September 20 at 9:05 AM
News IconUnder the Microscope: Getting a Closer Look at Shares of Aegerion Pharmaceuticals, Inc. (NASDAQ:AEGR) - Duncan Research (NASDAQ:AEGR)
www.duncanindependent.com - September 19 at 4:10 PM
News IconKeen Investors Seek Information on Aegerion Pharmaceuticals, Inc. (NASDAQ:AEGR) - Duncan Research (NASDAQ:AEGR)
www.duncanindependent.com - September 16 at 3:21 PM
News IconHealthcare Master Fun Broadfin Buys 276000 Shares of Aegerion Pharmaceuticals Inc. (AEGR) Stock - National Daily Press (NASDAQ:AEGR)
www.nationaldailypress.com - September 16 at 3:21 PM
News IconStock Update, a Closer Look at Aegerion Pharmaceuticals, Inc. (NASDAQ:AEGR) - Duncan Research (NASDAQ:AEGR)
www.duncanindependent.com - September 15 at 8:30 PM
News IconKeen Investors Narrowing Their Focus on Aegerion Pharmaceuticals, Inc. (NASDAQ:AEGR) - Duncan Research (NASDAQ:AEGR)
www.duncanindependent.com - September 14 at 3:20 PM
insidermonkey.com logoAegerion Pharmaceuticals Inc. (AEGR): Broadfin Capital Raises Its Stake Ahead of Merger - Insider Monkey (blog) (NASDAQ:AEGR)
www.insidermonkey.com - September 14 at 3:20 PM
News IconAegerion Pharmaceuticals Inc. (AEGR): Broadfin Capital Raises Its Stake Ahead of Merger (NASDAQ:AEGR)
feedproxy.google.com - September 14 at 1:55 PM
capitalcube.com logoETF’s with exposure to Aegerion Pharmaceuticals, Inc. : September 13, 2016 (NASDAQ:AEGR)
www.capitalcube.com - September 13 at 3:18 PM
News IconAnalysts Place Aegerion Pharmaceuticals, Inc. (NASDAQ:AEGR) Under the Lens of the Microscope - Post News (NASDAQ:AEGR)
www.kentuckypostnews.com - September 12 at 8:07 AM
live-pr.com logoAegerion Pharmaceuticals, Inc. (AEGR) - Financial and Strategic SWOT Analysis Review - New Report Available (NASDAQ:AEGR)
www.live-pr.com - September 7 at 12:17 PM
capitalcube.com logoETF’s with exposure to Aegerion Pharmaceuticals, Inc. : August 30, 2016 (NASDAQ:AEGR)
www.capitalcube.com - August 30 at 12:32 PM
investornewswire.com logoAegerion Pharmaceuticals, Inc. (NASDAQ:AEGR) Gets 0 Recommendations To Sell - Investor Newswire (NASDAQ:AEGR)
www.investornewswire.com - August 27 at 3:20 PM
News IconAegerion Pharmaceuticals, Inc. (NASDAQ:AEGR) Analyst Opinion - The Independent Republic (NASDAQ:AEGR)
theindependentrepublic.com - August 24 at 3:22 PM
News IconIs it Time to Buy Aegerion Pharmaceuticals, Inc. (NASDAQ:AEGR)? The Consensus Is In - Post News (NASDAQ:AEGR)
www.kentuckypostnews.com - August 22 at 8:07 AM
investornewswire.com logoWill Aegerion Pharmaceuticals, Inc. (NASDAQ:AEGR) Hit $2 Price Target? - Investor Newswire (NASDAQ:AEGR)
www.investornewswire.com - August 20 at 3:22 PM
finance.yahoo.com logoAEGERION PHARMACEUTICALS, INC. Financials (NASDAQ:AEGR)
finance.yahoo.com - August 19 at 3:43 PM
finance.yahoo.com logoGainey McKenna & Egleston Announces A Class Action Lawsuit Has Been Filed Against Aegerion Pharmaceuticals, Inc. (AEGR) (NASDAQ:AEGR)
finance.yahoo.com - August 17 at 3:21 PM
capitalcube.com logoETF’s with exposure to Aegerion Pharmaceuticals, Inc. : August 12, 2016 (NASDAQ:AEGR)
www.capitalcube.com - August 12 at 3:24 PM
capitalcube.com logoAegerion Pharmaceuticals, Inc. :AEGR-US: Earnings Analysis: Q2, 2016 By the Numbers : August 11, 2016 (NASDAQ:AEGR)
www.capitalcube.com - August 11 at 12:33 PM
globenewswire.com logoAegerion Pharmaceuticals Announces Second Quarter 2016 Financial Results - GlobeNewswire (press release) (NASDAQ:AEGR)
globenewswire.com - August 10 at 3:40 PM
sg.finance.yahoo.com logoAegerion reports 2Q loss (NASDAQ:AEGR)
sg.finance.yahoo.com - August 9 at 9:23 PM
feeds.reuters.com logoBRIEF-Aegerion Pharmaceuticals announces Q2 2016 financial results (NASDAQ:AEGR)
feeds.reuters.com - August 9 at 5:37 PM
biz.yahoo.com logoAEGERION PHARMACEUTICALS, INC. Files SEC form 8-K, Other Events, Financial Statements and Exhibits (NASDAQ:AEGR)
biz.yahoo.com - August 8 at 3:20 PM
ftsenews.co.uk logoAegerion Pharmaceuticals, Inc. (NASDAQ:AEGR) Updated Price Targets - FTSE News (NASDAQ:AEGR)
www.ftsenews.co.uk - August 1 at 8:06 AM
equities.com logoAegerion Pharmaceuticals Inc. (AEGR) Drops 5.16% on July 28 ... - Equities.com (NASDAQ:AEGR)
www.equities.com - July 30 at 3:25 PM
equities.com logoAegerion Pharmaceuticals Inc. (AEGR) Jumps 7.64% on July 27 - Equities.com (NASDAQ:AEGR)
www.equities.com - July 28 at 11:57 AM
News IconEquity Roundup: Stock Performance Focus on Aegerion Pharmaceuticals, Inc. (NASDAQ:AEGR) - Press Telegraph (NASDAQ:AEGR)
presstelegraph.com - July 23 at 3:20 PM
News IconStock Displaying Signs of a Downtrend: Aegerion Pharmaceuticals, Inc. (NASDAQ:AEGR) - Press Telegraph (NASDAQ:AEGR)
presstelegraph.com - July 23 at 3:20 PM
investornewswire.com logoIs $2 Price Target Attainable For Aegerion Pharmaceuticals, Inc. (NASDAQ:AEGR)? - Investor Newswire (NASDAQ:AEGR)
www.investornewswire.com - July 23 at 3:20 PM
kcregister.com logoAegerion Pharmaceuticals, Inc. (NASDAQ:AEGR) Decreased -2.61%: Ligand Pharmaceuticals Incorporated (NASDAQ ... - KC Register (NASDAQ:AEGR)
www.kcregister.com - July 22 at 3:19 PM

Social

Aegerion Pharmaceuticals (NASDAQ:AEGR) Chart for Friday, September, 30, 2016


Last Updated on 9/30/2016 by MarketBeat.com Staff